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Mechanism and function of DNA replication-
independent DNA-protein crosslink repair via the
SUMO-RNF4 pathway
Julio C Y Liu1,† , Ulrike K€uhbacher1,† , Nicolai B Larsen1, Nikoline Borgermann1,
Dimitriya H Garvanska1, Ivo A Hendriks1 , Leena Ackermann1, Peter Haahr2 , Irene Gallina1,
Claire Guerillon1 , Emma Branigan3, Ronald T Hay3 , Yoshiaki Azuma4 , Michael Lund Nielsen1,
Julien P Duxin1,* & Niels Mailand1,5,**
Abstract
DNA-protein crosslinks (DPCs) obstruct essential DNA transactions,
posing a serious threat to genome stability and functionality. DPCs
are proteolytically processed in a ubiquitin- and DNA replication-
dependent manner by SPRTN and the proteasome but can also be
resolved via targeted SUMOylation. However, the mechanistic
basis of SUMO-mediated DPC resolution and its interplay with
replication-coupled DPC repair remain unclear. Here, we show that
the SUMO-targeted ubiquitin ligase RNF4 defines a major pathway
for ubiquitylation and proteasomal clearance of SUMOylated DPCs
in the absence of DNA replication. Importantly, SUMO modifi-
cations of DPCs neither stimulate nor inhibit their rapid DNA
replication-coupled proteolysis. Instead, DPC SUMOylation provides
a critical salvage mechanism to remove DPCs formed after DNA
replication, as DPCs on duplex DNA do not activate interphase DNA
damage checkpoints. Consequently, in the absence of the SUMO-
RNF4 pathway cells are able to enter mitosis with a high load of
unresolved DPCs, leading to defective chromosome segregation and
cell death. Collectively, these findings provide mechanistic insights
into SUMO-driven pathways underlying replication-independent
DPC resolution and highlight their critical importance in maintain-
ing chromosome stability and cellular fitness.
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ubiquitin
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Introduction
Proteins acting on or residing in proximity to DNA can become
covalently trapped, giving rise to DNA-protein crosslinks (DPCs).
These bulky lesions can undermine the integrity and functionality of
the genome, as DPCs interfere with essential DNA-associated trans-
actions including DNA replication and transcription. In addition to
the accidental trapping of enzymes forming covalent intermediates
with DNA during catalysis, DPCs can be generated with varying effi-
cacy by a wide range of both endogenous and exogenous agents
including reactive aldehydes and commonly used chemotherapeutic
drugs such as topoisomerase inhibitors and cisplatin (Ide et al,
2011; Tretyakova et al, 2015; K€uhbacher & Duxin, 2020). The action
of DPC-inducing genotoxins and the stochastic trapping of proteins
on DNA together underlie an enormous diversity of DPCs, which
differ with respect to at least three basic parameters: the identity of
the crosslinked protein, the chemical nature of the covalent linkage
formed between DNA and the protein adduct, and the structure of
the DNA flanking the DPC. Faced with the formidable challenge of
recognizing and repairing a highly diverse range of DPCs, eukaryotic
cells possess a versatile toolbox of DPC resolution factors and mech-
anisms, whose complexity has become apparent through extensive
research efforts over the past few years. A central strategy for
resolving DPCs conserved from yeast to humans involves DNA
replication-coupled mechanisms targeting the protein component of
the DPC. In particular, the SprT-type metalloproteases Wss1 (yeast)
and SPRTN (higher eukaryotes) have firmly established key roles as
replication-coupled DPC repair factors that proteolytically process
covalent protein adducts to facilitate replication past the lesions
(Duxin et al, 2014; Stingele et al, 2014; Stingele et al, 2016; Vaz
et al, 2016; Larsen et al, 2019). While SPRTN can degrade a wide
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range of different protein substrates and could in principle act on
replisome-associated proteins in a non-specific manner with poten-
tially deleterious consequences, a range of elegant regulatory mech-
anisms ensure exquisite selectivity of SPRTN for cleaving DPCs.
These include a ubiquitylation–acetylation switch that controls
SPRTN chromatin association and dual DNA-binding domains that
specifically target its protease activity to the junction between
single- and double-stranded DNA (ssDNA and dsDNA) formed when
nascent DNA strands stall at a DPC (Stingele et al, 2016; Larsen
et al, 2019; Li et al, 2019; Huang et al, 2020; Reinking et al, 2020).
In addition to SPRTN, we recently demonstrated that the protea-
some is targeted to ubiquitylated DPCs and promotes an alternative
SPRTN-independent protease-driven DPC-processing pathway
during DNA replication (Larsen et al, 2019). Moreover, recent
evidence suggests that additional proteases, including DDI1/2 and
FAM111A, may also contribute to DNA replication-dependent DPC
processing (Kojima et al, 2020; Serbyn et al, 2020). Collectively,
these mechanisms ensure highly efficient clearance of DPCs encoun-
tered during DNA replication to mitigate their adverse impact on
genome duplication. Reflecting the physiological importance of such
mechanisms, SPRTN mutations in humans give rise to a rare
syndrome characterized by premature ageing and increased cancer
susceptibility (Lessel et al, 2014).
Despite the efficiency of DNA replication-coupled DPC resolution
pathways, these mechanisms are unlikely to offer full protection
from the collective threat posed by DPCs, which can arise during any
stage of the cell cycle. For instance, DPCs formed after DNA replica-
tion may be out of reach for DNA replication-coupled repair mecha-
nisms, and it is conceivable that an inability to resolve such lesions
could endanger subsequent faithful chromosome segregation. Like-
wise, non-dividing cells, particularly long-lived cells such as
neurons, likely require DPC recognition and resolution mechanisms
to avoid progressive accumulation of these lesions, which could
undermine long-term cellular fitness. Indeed, previous findings
raised the possibility that cells are able to resolve DPCs in a manner
that is uncoupled from the replication fork and that the small
ubiquitin-like modifier SUMO may have a key role in this process.
Specifically, we recently demonstrated that DNMT1 DPCs, which
can be generated post-replicatively in genomic DNA by treatment
with the cytosine analogue 5-aza-20-deoxycytidine (5-azadC) and are
not accompanied by DNA strand breaks, are not resolved by SPRTN
but undergo robust and direct SUMOylation, a modification that is
essential for the subsequent removal of these lesions (Borgermann
et al, 2019). Similarly, both Topoisomerase 1 and 2 (TOP1 and
TOP2) cleavage complexes, which are flanked by DNA breaks, are
modified by SUMOylation to promote their clearance, and available
evidence indicates that the resolution of this type of DPC occurs effi-
ciently outside S phase (Mao et al, 2000; Mo et al, 2002; Heideker
et al, 2011; Steinacher et al, 2013; Schellenberg et al, 2017; Sharma
et al, 2017; Wei et al, 2017; Sun et al, 2020). We and others recently
showed that the SprT protease ACRC (also known as GCNA) is a
putative DPC protease that interacts with SUMOylated DPCs via
tandem SUMO-interacting motifs (SIMs) (Borgermann et al, 2019;
Bhargava et al, 2020; Dokshin et al, 2020). However, the expression
and function of ACRC/GCNA appear to be largely confined to germ-
line cells (Carmell et al, 2016). Thus, how SUMOylation of DPCs, in
particular those residing at uninterrupted duplex DNA, drives lesion
processing and resolution, its interrelation with DNA replication-
coupled DPC repair and relative biological importance for preventing
genomic instability remain unclear.
In this study, we addressed these important questions. We demon-
strate that DPCs on duplex DNA are SUMOylated in the absence of
DNA replication and subsequently targeted for proteasomal degrada-
tion by the SUMO-targeted ubiquitin ligase (STUbL) RNF4. SUMOyla-
tion of DPCs neither stimulates nor inhibits their DNA replication-
dependent proteolysis. Instead, the SUMO-RNF4 pathway provides
an independent salvage route to remove DPCs formed or persisting
after DNA replication. Notably, we show that cells harbouring DPCs
on duplex DNA do not activate the interphase DNA damage check-
point and enter mitosis even in the presence of a high load of protein
adducts, leading to defective chromosome segregation and loss of
viability. Together, these findings reveal the mechanistic basis of
SUMO-driven, DNA replication-independent DPC resolution and
underscore its critical importance in safeguarding genome integrity.
Results
RNF4 promotes resolution of SUMO-modified DPCs in
duplex DNA
To understand the mechanistic basis of how SUMOylation promotes
removal of DPCs, we first monitored the resolution kinetics for
DNMT1 DPCs that are formed in the wake of the replication fork
following 5-azadC incorporation into genomic DNA during replica-
tion. To this aim, cells were synchronized in early S phase, exposed
to a brief (30-min) pulse of 5-azadC in order to ensure even incorpo-
ration of this nucleotide analogue into genomic DNA of all cells, and
analysed at different time points (Fig 1A). Methylation of 5-azadC by
DNMT-type methyltransferases, in particular DNMT1 that methy-
lates CpG motifs in newly replicated DNA to maintain DNA methyla-
tion patterns, leads to their covalent crosslinking to DNA. Cell
fractionation revealed that the SUMO-dependent modification and
resolution of trapped DNMT1 molecules proceeded with rapid kinet-
ics, as the bulk of SUMOylated DNMT1 DPCs were cleared from
chromatin within 3-4 h after 5-azadC treatment (Fig 1A). This was
accompanied by a complete loss of the soluble pool of DNMT1 mole-
cules (Fig 1A), suggesting that crosslinked DNMT1 molecules are
degraded following their entrapment on chromatin. Complementing
this analysis, we used an automated high throughput imaging
approach to quantify DNMT1 DPC resolution kinetics across large
populations of individual cells, using detergent-resistant DNMT1
nuclear foci as a readout for endogenous DNMT1 molecules immobi-
lized on chromatin upon 5-azadC treatment (Borgermann et al,
2019). In this assay, trapped DNMT1 molecules were largely cleared
from chromatin by 3 h after 5-azadC removal, paralleling DNMT1
DPC resolution kinetics observed by chromatin fractionation (Figs
1A and B, and EV1A). Blocking DNMT1 DPC SUMOylation by means
of the SUMO E1 inhibitor ML-792 (SUMOi; (He et al, 2017))
suppressed the removal of DNMT1 DPCs as we previously reported
(Fig 1C) (Borgermann et al, 2019). Likewise, inhibiting the protea-
some or overall ubiquitylation also impaired the removal of DNMT1
DPCs (Figs 1C and EV1B), and the formation of DNMT1 DPCs was
accompanied by their modification with K48-linked ubiquitin chains
(Fig 1D). These observations suggested the involvement of STUbL
activity in promoting ubiquitylation of DNMT1 DPCs downstream of
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their SUMOylation. Knockdown of the known human STUbLs, RNF4
and RNF111, revealed that RNF4 but not RNF111 was required for
5-azadC-induced ubiquitylation of DNMT1, whereas it was dispens-
able for DNMT1 SUMOylation (Figs 1E and EV1C and D). Consis-
tently, depletion of RNF4 but not RNF111 impaired the timely
clearance of 5-azadC-induced DNMT1 DPCs (Figs 1F and G, and
EV1E–H). In agreement with a role of RNF4 in promoting resolution
of SUMOylated DNMT1 DPCs, RNF4 was recruited to DNMT1 DPC
sites and accumulated on chromatin upon 5-azadC-induced DNMT1
DPC formation in a SUMO-dependent manner (Fig 1H and I). More-
over, wild-type (WT) RNF4 but not catalytically inactive or SIM-
deficient mutants promoted ubiquitylation of SUMOylated DNMT1
isolated from 5-azadC- but not mock-treated cells in vitro, providing
direct evidence that SUMOylation of DNMT1 renders it susceptible to
modification by RNF4 STUbL activity (Fig 1J). We previously
showed that while DNMT1 is the main cellular target of 5-azadC-
induced SUMOylation, a small range of additional proteins including
known DNMT1-binding factors also display increased SUMOylation
upon DNMT1 DPC formation (Borgermann et al, 2019). Because loss
of RNF4 led to a marked delay in reversing overall 5-azadC-induced
chromatin SUMOylation (Figs 1F and EV1E and G), it is likely that
RNF4 STUbL activity is not exclusively targeted to DPCs but also
impacts other SUMOylated proteins at DPC sites to facilitate lesion
removal and re-establishment of a normal chromatin state. Support-
ing a general role of RNF4 in resolving DPCs in uninterrupted duplex
DNA, we found that it also underwent strong enrichment on chro-
matin upon treatment with the non-specific DPC inducer formalde-
hyde (Fig EV1I), which we previously showed triggers a robust
SUMOylation response (Borgermann et al, 2019). Moreover, RNF4
was required for counteracting chromatin-associated SUMO2/3 foci
resulting from formaldehyde-induced DPC formation (Fig EV1J and
K). We conclude that RNF4-mediated ubiquitylation and subsequent
proteasomal degradation defines an important pathway for SUMO-
dependent resolution of DPCs. We note, however, that unlike
complete inhibition of DNMT1 DPC degradation by SUMOi, loss of
RNF4 only partially suppressed the removal of SUMO-modified
DNMT1 DPCs (Figs 1G and EV1E and F), suggesting the existence of
additional, SUMO-driven but RNF4-independent mechanisms for
post-replicative DNMT1 DPC resolution.
PIAS4 promotes DPC SUMOylation in the absence of DNA
replication in Xenopus egg extracts
To further understand the mechanistic basis of DPC SUMOylation
and its interplay with replication-coupled DPC repair, we turned to
the cell-free Xenopus egg extract system, taking advantage of our
previous observation that defined DPCs involving the HpaII methyl-
transferase (M.HpaII) linked to duplex plasmid DNA undergo
SUMOylation when incubated in nucleoplasmic egg extracts (NPE)
in the absence of DNA replication (Larsen et al, 2019) (Fig 2A).
Under these conditions, M.HpaII DPC SUMOylation occurred
progressively over a 3-h time course and was enhanced when a
SUMO-fused M.HpaII protein (SUMODGG-M.HpaII) was crosslinked
to DNA (p4xDPCSUMO) (Fig 2B; compare lanes 1–5 to 6–10). These
findings reinforce the notion that SUMOylation is a principal modifi-
cation impacting DPCs recognized outside the context of DNA repli-
cation. However, for reasons addressed below, unlike DNMT1 DPCs
in human cells, SUMOylated M.HpaII DPCs residing on duplex DNA
did not undergo further processing by ubiquitylation in NPE, as
evidenced by the ability of the SUMO protease Ulp1 to quantitatively
remove all modified forms of M.HpaII (Fig 2C). To address whether
the SUMO response was specific to DPCs or could also occur on
proteins that are non-covalently trapped on chromatin, we moni-
tored PARP1 modifications on sperm chromatin following DNA
damage by UV treatment in the presence or absence of PARP inhibi-
tors, which stabilize PARP1 association with DNA (Pommier et al,
2016; Zandarashvili et al, 2020). Previous studies in human cells
and Xenopus egg extracts indicated that PARP1 is SUMOylated in a
chromatin-dependent manner (Martin et al, 2009; Messner et al,
2009; Ryu et al, 2010; Zilio et al, 2013). Consistently, while a frac-
tion of PARP1 appeared mono-SUMOylated on chromatin irrespec-
tively of DNA damage or PARP inhibition, combining these
treatments specifically induced PARP1 poly-SUMOylation (Figs 2D
and EV2A and B), indicating that proteins that are non-covalently
immobilized on DNA can also be targeted for poly-SUMOylation.
CHROMASS analysis (R€aschle et al, 2015) identified PIAS4 (also
known as PIASc) as a SUMO E3 ligase that was enriched on sperm
chromatin upon PARP1 inhibition in the presence of DNA damage
in a SUMO-dependent manner (Figs 2E and EV2B; Dataset EV1). In
◀ Figure 1. RNF4 promotes resolution of SUMO-modified DNMT1 DPCs.
A HeLa cells released from double thymidine synchronization in early S phase were treated with 5-azadC for 30 min, washed and collected at the indicated times.
Soluble and chromatin-enriched fractions were immunoblotted with indicated antibodies.
B U2OS cells treated as in (A) were pre-extracted and immunostained with DNMT1 antibody. DNMT1 foci formation was analysed by quantitative image-based
cytometry (QIBC) (red bars, mean; > 1,500 cells analysed per condition). Data are representative of three independent experiments. See also Fig EV1A.
C As in (B), except that cells were pre-treated with the proteasome inhibitor MG132 and/or SUMOi for 30 and 15 min, respectively, before exposure to 5-azadC (red bars,
mean; > 1,900 cells analysed per condition). Data are representative of three independent experiments.
D HeLa cells stably expressing GFP-DNMT1 were treated or not with 5-azadC for 30 min, collected and subjected to GFP immunoprecipitation under denaturing
conditions, and immunoblotted with indicated antibodies.
E HeLa/GFP-DNMT1 cells transfected with indicated siRNAs were processed as in (D).
F Immunoblot analysis of soluble and chromatin-enriched fractions of HeLa cells transfected with indicated siRNAs, left untreated or exposed to 5-azadC for 30 min
and collected at the indicated times.
G U2OS cells transfected with indicated siRNAs were treated with 5-azadC for 30 min and processed for QIBC analysis of DNMT1 foci counts as in (B) (red bars, mean;
> 5,600 cells analysed per condition). Data are representative of three independent experiments.
H Representative images of U2OS cells transfected with indicated siRNAs followed by mCherry-RNF4 expression plasmid. Cells were treated with 5-azadC in the
presence or absence of SUMOi, fixed 2 h later, pre-extracted and co-immunostained with DNMT1 and SUMO2/3 antibodies. Scale bar, 10 µm.
I Immunoblot analysis of soluble and chromatin-enriched fractions of HeLa cells treated with 5-azadC and/or SUMOi as indicated.
J GFP-tagged DNMT1 from extracts of HeLa/GFP-DNMT1 cells treated or not with 5-azadC was immobilized on GFP-Trap agarose, subjected to stringent washing to
remove proteins non-covalently bound to GFP-DNMT1 and incubated with recombinant HA-ubiquitin, E1 and E2 (UbcH5a) enzymes and RNF4 proteins (STUbL
reaction) at 37°C for 1 h. Samples were then subjected to immunoblotting to assay for RNF4-dependent STUbL activity towards GFP-DNMT1.
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line with this, immunodepletion of PIAS4 from NPE completely
abrogated SUMOylation of M.HpaII DPCs (Figs 2F and EV2C). PIAS4
depletion also severely inhibited poly-SUMOylation of crosslinked
SUMO-M.HpaII, although in this case residual SUMOylation of the
DPC was observed, suggesting that in the absence of PIAS4
another SUMO E3 ligase may contribute to extending some M.HpaII
SUMO modifications (Fig 2G). Importantly, M.HpaII DPC poly-
SUMOylation was restored by supplementing extracts with recombi-
nant WT PIAS4 but not a mutant lacking its dual SIMs (Kaur et al,
2017), which showed defective accumulation on damaged chro-
matin (Figs 2F and G, and EV2D–G), consistent with the SUMO-
dependent enrichment of PIAS4 detected by CHROMASS. PIAS4 was
also responsible for PARP1 SUMOylation both in the presence or
absence of DNA damage (Fig EV2H and I). Furthermore, purified
PIAS4 stimulated poly-SUMOylation of M.HpaII DPCs in vitro
(Fig 2H). Collectively, these data show that DPC SUMOylation can
occur in the complete absence of DNA replication and suggest a
primary role of PIAS4 in this response in Xenopus egg extracts.
In cells, consistent with our observations in Xenopus egg
extracts, PIAS4 was recruited to DNMT1 DPC sites in a
SUMOylation-dependent manner and displayed increased binding to
DNMT1 upon DPC formation (Figs 2I and J, and EV2J), suggesting
its engagement in promoting SUMO modification of these DPCs.
However, in contrast to its major role observed in Xenopus egg
extracts, depletion of PIAS4 had no overt impact on DNMT1 DPC
SUMOylation (Figs 2K and EV2K and L). In fact, individual deple-
tion of established SUMO E3 ligases did not impair overall DNMT1
DPC SUMOylation (Fig 2K), suggesting a possible redundancy
between PIAS4 and other SUMO E3s in driving this response, in line
with its strong magnitude. Supporting this notion, SUMO-dependent
recruitment of PIAS4 to DNMT1 DPCs occurred normally in cells
devoid of PIAS4 catalytic activity (Fig EV2M and N), suggesting the
involvement of one or more other SUMO E3s in promoting PIAS4
accumulation at DPC sites. The differential requirement of PIAS4 for
DPC SUMOylation in cells and Xenopus egg extracts could reflect
the distinct chromatin environments harbouring the DPCs in the
two systems and/or the absence in egg extracts of active transcrip-
tion, which may provide an additional DPC-sensing mechanism
in cells.
DPC SUMOylation neither inhibits nor stimulates replication-
coupled DPC repair
In contrast to DNA replication-independent DPC SUMOylation, our
previous work showed that during DNA replication DPCs are rapidly
ubiquitylated by TRAIP and subsequently degraded by SPRTN and
the proteasome (Larsen et al, 2019). We therefore utilized the notion
that SUMOylated DPCs are stable in NPE to analyse the impact of
DPC SUMOylation on replication-coupled DPC repair. To this end, a
plasmid in which M.HpaII is crosslinked to the leading strands
(p2xDPCLeads) was first replicated in egg extract in the presence or
absence of ubiquitin or SUMO E1 inhibitors. During replication of
p2xDPCLeads, converging forks transiently stall at the DPC, after
which daughter plasmid molecules are resolved (Larsen et al, 2019)
(Fig 3A). The daughter molecules containing the DPC initially
migrate as an open circular (OC) species (Fig 3B, lane 2 (red arrow-
head)) and are then gradually converted to a supercoiled (SC) repair
product through proteolysis of the DPC and translesion DNA synthesis
(TLS) across the resulting peptide adduct (Fig 3B, lanes 1–5). As
expected, inhibition of ubiquitylation suppressed replication-coupled
◀ Figure 2. DPC SUMOylation occurs in Xenopus egg extracts and is mediated by PIAS4.
A M.HpaII was crosslinked into a plasmid to generate p4xDPC and then incubated in nucleoplasmic egg extracts (NPE) in the presence or absence of 50 µM of SUMOi.
DPC pull-down under stringent conditions was performed at the indicated time points, and the recovered samples were immunoblotted for crosslinked M.HpaII
(Larsen et al, 2019). p4xDPC, which contains four M.HpaII DPCs, was used to increase sensitivity towards modified M.HpaII species. Identical results were obtained
with plasmids containing one or four DPCs.
B p4xDPC or p4xDPCSUMO (generated by crosslinking SUMODGG-M.HpaII) were incubated in NPE and DPC pull-down performed as in (A). Note that priming M.HpaII
with SUMO stimulates rapid poly-SUMOylation of the DPC in NPE. Thus, this substrate was used in many subsequent experiments to stimulate DPC poly-
SUMOylation.
C p4xDPCSUMO was incubated in NPE and plasmids analysed as in (A). Following DPC pull-down, the samples were split and either left untreated or treated with the
SUMO protease Ulp1.
D Sperm chromatin treated with 2,000 J/m2 of UV-C was incubated in non-replicating egg extracts in the presence or absence of the indicated PARP inhibitors (PARPi;
Veliparib (50 µM), Olaparib (50 µM), Talazoparib (10 µM)). At the indicated time points, chromatin was recovered via chromatin spin-down and samples were
immunoblotted with indicated antibodies.
E Plot illustrating protein recruitment to UV-treated sperm chromatin in the presence or absence of Talazoparib and SUMOi, as determined by CHROMASS analysis
(Dataset EV1). Red dots indicate the proteins that are significantly enriched on sperm chromatin in the presence of PARPi in a SUMO-dependent manner (n = 4
biochemical replicates; FDR < 5% corresponds to a permutation-based FDR-adjusted q-value of < 0.05). Note that different isoforms of the same protein (e.g. ATF7IP)
can sometimes be detected.
F NPE was either mock- or PIAS4-depleted, and recombinant xPIAS4 was added where indicated to a final concentration of 10 ng/µl. Protein samples were
immunoblotted with the indicated antibodies.
G Samples from (F) were added to p4xDPCSUMO for the indicated times and recovered via DPC pull-down as in (A).
H pDPC or a plasmid containing M.HpaII crosslinked to ssDNA (pDPCssDNA) (Larsen et al, 2019) was incubated with SUMO E1 and E2 enzymes and SUMO, in the
presence or absence of recombinant xPIAS4. Samples were recovered by DPC pull-down and blotted against M.HpaII as in (A).
I Representative images of U2OS cells transfected with Myc-PIAS4 expression plasmid that were left untreated or exposed to 5-azadC in the presence or absence of
SUMOi, fixed 2 h later, pre-extracted and co-immunostained with DNMT1 and Myc antibodies. Scale bar, 5 µm.
J HeLa or HeLa/GFP-DNMT1 cells left untreated or exposed to 5-azadC for 30 min were lysed and subjected to GFP IP under stringent conditions. After extensive
washing, individual IPs were incubated with an equal amount (800 µg) of whole cell lysate of HeLa cells transfected with Myc-PIAS4 expression construct (Fig EV2J),
washed and immunoblotted with antibodies to Myc, SUMO2/3 and GFP. *, cross-reactive band.
K HeLa/GFP-DNMT1 cells transfected with previously validated siRNAs targeting established SUMO E3 ligases (Fig EV2L and Methods section) were treated with
5-azadC for 30 min, collected and subjected to GFP immunoprecipitation under denaturing conditions, and immunoblotted with antibodies to SUMO1, SUMO2/3,
ubiquitin and GFP.
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DPC repair, evidenced by the accumulation of OC molecules, while
addition of SUMOi had no effect (Fig 3B, lanes 11–15; Fig EV3A).
Consistently, M.HpaII DPCs were ubiquitylated and degraded
normally in the presence of SUMOi (Fig 3C, lanes 13–18; Fig EV3B).
Likewise, SUMO-fused M.HpaII, which induced some poly-
SUMOylation during the licensing reaction (Fig 3C, lane 7), did not
impair DPC ubiquitylation and repair during DNA replication
(Fig 3B, lanes 6–10; Fig 3C, lanes 7–12), nor in the absence of a
replication fork when the DPC was placed on ssDNA (Fig EV3C and
D). Interestingly, PIAS4-dependent DPC SUMOylation in vitro was
not restricted to DPCs on dsDNA but also occurred on DPCs on
ssDNA (Fig 2H), suggesting that in contrast to replication-dependent
mechanisms that target DPCs on ssDNA, the SUMO pathway can
sense DPCs residing in different DNA contexts. We conclude that
DPC SUMOylation is neither inhibitory nor stimulatory towards
replication-coupled DPC repair. Instead, it likely provides an alterna-
tive and independent modification route when DPC repair cannot be
accomplished via DNA replication-associated mechanisms.
RNF4 targets SUMO-modified DPCs in a DNA replication-
independent manner
Unlike DNMT1 DPCs in human cells, DPC SUMOylation in NPE did
not trigger RNF4-mediated ubiquitylation and degradation. By gener-
ating an antibody against Xenopus RNF4, we realized that it is only
present at low nanomolar concentrations in egg extracts (Fig EV3E),
potentially explaining why SUMOylated DPCs were not further
modified by ubiquitylation. Importantly, by supplementing NPE with
recombinant RNF4 we could recapitulate DPC ubiquitylation in the
complete absence of DNA replication, and this effect was dependent
on RNF4 catalytic activity (Figs 3D and E, and EV3F). A similar effect
was observed when supplementing NPE with whole egg CSF-
arrested extracts, which contain slightly higher concentrations of
RNF4 (Fig EV3E). In this setting, the mitosis-like extract induced
DPC modifications that contained both ubiquitin and SUMO moieties
and were fully suppressed when de novo SUMOylation was inhibited
by addition of a dominant-negative SUMO E2 enzyme (UBC9DN)
(Fig 3F and G). Likewise, DPC ubiquitylation could be observed
when SUMOylated DPCs were isolated following incubation in NPE
and transferred into fresh CSF-arrested extracts (Fig 3I, lane 1-3).
This ubiquitylation was impaired by depletion of RNF4 and restored
by adding back recombinant WT but not catalytically inactive RNF4
to the extracts (Fig 3H–J). Correspondingly, while CSF-arrested
extracts were less efficient than NPE in promoting M.HpaII DPC
SUMOylation and had lower PIAS4 concentration, DPC SUMOylation
and ubiquitylation in this extract could be strongly enhanced by
addition of recombinant PIAS4 (Fig EV3G–I). Addition of WT RNF4
markedly accelerated ubiquitylation of SUMOylated DPCs in both
CSF-arrested extracts (Fig 3J, lanes 8–10) and NPE (Fig EV3J and K).
Under these conditions the DPCs underwent degradation, which was
partially inhibited upon proteasome depletion (Fig 3K and L, and
EV3L and M) or inhibition (Fig EV3K, lanes 11–13), as observed in
cells. Moreover, addition of a pan-CDK inhibitor to CSF-arrested
extracts inhibited RNF4-dependent DPC ubiquitylation (Fig EV3N
and O), consistent with a previous report indicating that RNF4 E3
ligase activity is stimulated by CDK activity (Luo et al, 2015). We
conclude from these findings that SUMOylated DPCs are directly
targeted by RNF4 STUbL activity in both human cells and Xenopus
egg extracts and that this process occurs in the complete absence of
DNA replication. Moreover, RNF4-dependent DPC ubiquitylation
may be potentiated in a post-replicative manner by the progressive
cell cycle-dependent increase in cyclin-CDK activity.
Unresolved DPCs in duplex DNA do not elicit an effective DNA
damage checkpoint
The mechanistic insights into SUMO-driven pathways for DNA
replication-independent resolution of DNMT1 DPCs described above
provided an opportunity to address if and how unresolved DPCs on
duplex DNA undermine genome stability and cellular fitness. To
◀ Figure 3. The SUMO-RNF4 DPC resolution pathway is independent of DNA replication and neither stimulates nor inhibits replication-coupled DPC repair.
A Scheme illustrating replication in egg extracts of p2xDPCLeads, a plasmid containing two M.HpaII crosslinked on opposite strands. Under these conditions, the vast
majority of replication forks encounter the DPC on their leading strand template (Larsen et al, 2019).
B p2xDPCLeads or p2xDPCSUMOLeads were replicated in egg extracts in the presence [a-32P]dATP. Where indicated, 50 µM of SUMOi was added to the extracts. Reaction
samples were analysed by native agarose gel electrophoresis. RI, replication intermediates; OC, open circular; SC, supercoiled. Red arrowheads indicate OC molecules
that have not yet undergone repair.
C Samples in (B) were recovered by DPC pull-down and immunoblotted for crosslinked M.HpaII.
D Scheme illustrating sequential SUMOylation and ubiquitylation of DPC-containing plasmids in non-replicating egg extracts. First, p4xDPCSUMO is incubated in NPE
for 60-90 min to achieve poly-SUMOylation of the DPCs. NPE is then supplemented with recombinant RNF4 to a final concentration of 7 ng/µl (E) or an equal
volume of CSF-arrested whole egg extract (F, G) to trigger DPC ubiquitylation.
E p4xDPCSUMO was incubated in NPE for 60 min and supplemented with buffer or recombinant RNF4 (WT or a catalytically inactive C130A mutant). At the indicated
time points following RNF4 addition, the DPC plasmid was recovered by DPC pull-down and immunoblotted against M.HpaII.
F pDPCSUMO was subjected to sequential extract addition as depicted in (D). Recombinant UBC9DN was added to NPE where indicated to block de novo SUMOylation.
At the indicated time points following addition of CSF-arrested egg extract, the plasmid was recovered via DPC pull-down and immunoblotted against M.HpaII.
G pDPCSUMO was subjected to sequential extract addition as depicted in (D). Ninety min after addition of CSF-arrested extract, samples were recovered via DPC pull-
down and treated with the SUMO protease Ulp1 or the ubiquitin protease Usp2 as indicated. Samples were then immunoblotted against M.HpaII.
H CSF-arrested extracts were either mock- or RNF4-depleted and recombinant His-RNF4 was supplemented to RNF4-depleted extracts to a final concentration of
7 ng/µl where indicated. Protein samples were immunoblotted with the indicated antibodies.
I p4xDPCSUMO was polySUMOylated in NPE, recovered via DPC pull-down and incubated in fresh CSF-arrested extract that was either mock- or RNF4-depleted. At
indicated time points following CSF extract addition, the plasmid was recovered and immunoblotted against M.HpaII.
J As in (I), but using RNF4-depleted CSF-arrested extracts reconstituted with recombinant RNF4 WT or C130A from (H).
K CSF-arrested extracts were either mock- or PSMA1-depleted. Protein samples were immunoblotted with the indicated antibodies.
L p4xDPCSUMO was subjected to sequential addition of NPE and CSF-arrested extract as in (I). CSF-arrested extracts from (K) were supplemented with recombinant
RNF4, and the DPC plasmid was recovered by DPC pull-down at the indicated time points and immunoblotted against M.HpaII.
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explore this, we pulse-labelled cells in late S phase with 5-azadC
and subsequently monitored the impact of RNF4 knockdown or
SUMO inhibition on DNMT1 DPC removal and cell cycle progres-
sion (Fig 4A). As expected, 5-azadC-induced DPCs generated in late
S phase were largely resolved by the time control cells entered mito-
sis (Fig 4B and C), consistent with their robust capacity for DNMT1
DPC resolution (Fig 1B). By contrast, both RNF4 depletion and
SUMOi treatment led to a persistence of DNMT1 DPCs in mitotic
cells (Fig 4B and C). Strikingly, whereas neither 5-azadC treatment
nor RNF4 depletion alone delayed cell cycle progression following
synchronization in early S phase, combined RNF4 knockdown and
5-azadC exposure led to a prominent accumulation of cells in G2/M
phase (Figs 4D and EV4A). Combining SUMOi and 5-azadC treat-
ment caused an even stronger accrual of cells in G2/M phase
(Fig 4E), in agreement with the more severe impact of SUMOi on
DNMT1 DPC resolution relative to RNF4 knockdown. Importantly,
knockdown of DNMT1 rescued the accumulation of G2/M phase
cells resulting from inhibition of SUMOylation or RNF4 depletion in
5-azadC-treated cells (Fig 4D and E), demonstrating that it was a
specific consequence of DNMT1 DPC formation. Several lines of
evidence from HeLa and non-transformed RPE-1 cells suggested that
impairment of DNMT1 DPC resolution leads to accumulation of cells
in mitosis rather than in G2 phase. First, exposing RNF4-depleted or
SUMOi-treated cells released from early S phase arrest to 5-azadC
had no overt impact on the kinetics with which the mitotic marker
Histone H3-pSer10 accumulated (Figs 4F and EV4B–D). Second,
live-cell imaging experiments showed that the timing of mitotic
entry, as assessed by nuclear envelope breakdown, of cells pre-
synchronized in S phase was not significantly altered by combined
5-azadC and SUMOi or RNF4 siRNA treatment (Fig 4G). Finally,
unlike genotoxic insults such as DNA breakage and replication
stress generated by exposure to ionizing radiation (IR) and hydrox-
yurea (HU), respectively, 5-azadC-induced DNMT1 DPCs did not
trigger detectable DNA damage checkpoint signalling in HeLa and
RPE-1 cells, regardless of whether DPC resolution was impaired by
RNF4 depletion (Figs 4H and EV4E). Likewise, whereas it potently
induces DPCs and an accompanying strong chromatin SUMOylation
response (Borgermann et al, 2019), formaldehyde only weakly acti-
vated canonical DNA damage signalling, possibly reflecting its abil-
ity to also generate other types of DNA damage (Fig EV4F).
Together, these findings suggest that human cells do not elicit an
effective DNA damage checkpoint response to DPCs in otherwise
undamaged duplex DNA and thus enter mitosis with normal kinet-
ics even in the face of a high load of these lesions, in contrast to
most other types of DNA damage.
Unresolved DPCs undermine faithful mitotic
chromosome segregation
Despite the apparent lack of a G2 checkpoint for sensing DPCs on
duplex DNA, preventing the timely resolution of these lesions never-
theless caused prominent accumulation of cells with G2/M DNA
content (Fig 4D and E). This suggested that unresolved DPCs might
interfere with proper progression through mitosis. To test this, we
used live-cell imaging to monitor how unresolved DPCs affect chro-
mosome segregation and cell division. While treatment with 5-
azadC, SUMOi or RNF4 siRNA alone had no significant impact on
the kinetics of mitotic progression, we observed a substantial delay
to anaphase onset following mitotic entry (marked by nuclear
envelope breakdown) in siRNF4- or SUMOi-treated cells exposed to
5-azadC, consistent with their accumulation in G2/M phase
(Fig 5A). Detailed inspection of mitotic progression revealed that a
large proportion of cells with unresolved DNMT1 DPCs showed a
marked delay in completing chromosome alignment at the meta-
phase plate, giving rise to defective chromosome segregation
(Fig 5B and C). Moreover, cells with high loads of 5-azadC-induced
DNMT1 DPCs due to RNF4 knockdown frequently displayed abor-
tive cytokinesis leading to nuclear abnormalities (Fig 5D). Suppres-
sion of the spindle assembly checkpoint (SAC) using an MPS1
kinase inhibitor (MPS1i) accelerated mitotic exit in RNF4-depleted
cells harbouring unresolved DNMT1 DPCs and enhanced aneu-
ploidy (Figs 5E and EV5A), suggesting that unlike interphase DNA
◀ Figure 4. DPCs on duplex DNA do not activate the DNA damage checkpoint.
A Outline of experimental set up to monitor DNMT1 DPC levels in S phase and mitotic cells.
B HeLa cells released from double thymidine block in early S phase were mock-treated or pulse-labelled for 30 min with 5-azadC in the presence of SUMOi in late S
phase. Following 5-azadC removal, cells were incubated with SUMOi and nocodazole, and mitotic cells were collected by shake-off, as outlined in (A). Soluble and
chromatin-enriched fractions were immunoblotted with indicated antibodies.
C U2OS cells transfected with indicated siRNAs and then treated as in (B) were collected in late S phase or mitosis (M), subjected to stringent pre-extraction and
immunostained with DNMT1 antibody. DNMT1 foci formation was quantified by QIBC analysis (red bars, mean; > 7,400 cells analysed per condition). Data are
representative of three independent experiments.
D HeLa cells transfected with indicated siRNAs and synchronized in early S phase by double thymidine block were pulse-labelled with 5-azadC in late S phase as
outlined in (A). Cells were then collected at the indicated times after 5-azadC withdrawal and analysed by flow cytometry. Data are representative of three
independent experiments. Proportion of cells with G2/M DNA content is indicated.
E HeLa cells transfected with indicated siRNAs were treated with 5-azadC and/or SUMOi in late S phase as outlined in (A). Cells were then collected at the indicated
times after 5-azadC withdrawal and analysed by flow cytometry. Data are representative of three independent experiments. Proportion of cells with G2/M DNA
content is indicated.
F HeLa cells transfected with indicated siRNAs were pulse-labelled or not with 5-azadC for 30 min in late S phase according to the experimental setup in (A).
Following 5-azadC withdrawal cells were incubated with nocodazole, collected at the indicated times and immunoblotted with indicated
antibodies.
G HeLa cells transfected or not with indicated siRNAs were synchronized in early S phase by double thymidine block, released and pulse-labelled 5,5 h later with 5-
azadC for 30 min in the presence or absence of SUMOi. Following 5-azadC removal, cells were subjected to live-cell imaging analysis, and the duration from late S
phase to mitotic entry (nuclear envelope breakdown (NEBD)) was quantified (red bars, median; at least 83 cells, pooled from three independent experiments, were
analysed per condition; **P < 0.01, ns: not significant, Mann–Whitney test).
H Immunoblot analysis of siRNA-treated HeLa cells that were exposed to indicated genotoxic agents and collected 1 h later.
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damage checkpoints DPCs on duplex DNA trigger activation of the
SAC. Importantly, formaldehyde-induced DPCs similarly prolonged
mitosis and led to a markedly elevated rate of defective chromo-
some segregation when their resolution was blocked by SUMOi (Fig
EV5B and C), suggesting this is a general effect of unrepaired DPCs
in otherwise undamaged duplex DNA. Finally, consistent with the
extensive chromosome segregation defects and resulting genomic
instability incurred by cells undergoing mitosis in the presence of
unresolved DNMT1 DPCs, loss of RNF4 functionality by indepen-
dent siRNAs or CRISPR/Cas9-mediated truncation hypersensitized
cells to 5-azadC (Figs 5F and G, and EV1C and H). Cells lacking
RNF4 also displayed increased sensitivity to formaldehyde
(Fig EV5D). Collectively, these data establish and underscore a
critical role of post-replicative, SUMO-driven DPC resolution mecha-
nisms in the maintenance of chromosome stability and cellular
fitness.
Discussion
Our recent work established an essential role of protein SUMOyla-
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Figure 6. Mechanism of SUMO-mediated DNA replication-independent DPC repair.
Scheme illustrating independent mechanisms of replication-coupled and SUMO-mediated replication-independent DPC repair available to cells. In the absence of RNF4-
mediated DPC resolution, cells containing high loads of DPCs generated after DNA replication fail to elicit a DNA damage checkpoint response and consequently enter
mitosis with unresolved DPCs, leading to chromosome segregation defects.
◀ Figure 5. Unresolved DPCs undermine faithful mitotic chromosome segregation and cellular fitness.
A HeLa cells transfected or not with indicated siRNAs were synchronized in early S phase by double thymidine block, released and pulse-labelled 5,5 h later with 5-
azadC for 30 min in the presence or absence of SUMOi. Following 5-azadC removal, cells were subjected to live-cell imaging analysis, and the duration of mitosis
(nuclear envelope breakdown (NEBD) to anaphase onset) was quantified (red bars, median; at least 72 cells, pooled from three independent experiments, were
analysed per condition; ****P < 0.0001, ns: not significant, Mann–Whitney test).
B Representative time-lapse sequences of mitotic progression in cells in (A). NEBD corresponds to t = 0. White arrowheads indicate cells undergoing division. Scale
bar, 10 µm.
C, D Quantification of mitotic defects in cells in (A) (mean; n = 3 independent experiments; > 97 cells quantified per condition; *P < 0.05, **P < 0.01, paired t-test).
E HeLa cells transfected with RNF4 siRNA were synchronized in early S phase by double thymidine block. Six hours after release from the block, cells were pulse-
labelled with 5-azadC for 30 min. Mitotic cells were isolated by shake-off 8 h later, washed and incubated or not with MPS1 inhibitor (MPS1i) and collected at the
indicated times. Cells were then processed for immunoblotting with indicated antibodies.
F Clonogenic survival of 5-azadC-treated HeLa cells transfected with indicated siRNAs (mean  SEM; n = 2 independent experiments).
G Clonogenic survival of 5-azadC-treated WT HAP1 cells and derivative cell lines expressing a truncated form of RNF4 lacking the RING domain (DRNF4; Fig EV1H)
(mean  SEM; n = 2 independent experiments).
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crosslinked protein (Borgermann et al, 2019). However, mechanisti-
cally how SUMOylation of DPCs on duplex DNA drives their
removal and its significance for genome stability maintenance
remained unclear. In addition, while available evidence suggests
that cells possess both DNA replication-coupled and -independent
mechanisms for clearing DPCs, the interrelationship between these
processes has not been directly studied. In the present study, we
addressed these important questions using both human cells and
Xenopus egg extracts. We demonstrate that the STUbL activity of
RNF4 towards SUMOylated DPCs is fully uncoupled from DNA repli-
cation and provides a major salvage route that is critical for remov-
ing DPCs prior to mitosis and thereby ensure proper cell division
and cellular fitness (Fig 6).
Replication-coupled and replication-independent DPC
repair pathways
While both replication-coupled and replication-independent resolu-
tion pathways can promote DPC proteolysis via the proteasome,
the former proceeds via direct DPC ubiquitylation by dedicated
replication fork-associated or ssDNA targeted ubiquitin ligases
including TRAIP and RFWD3 (Larsen et al, 2019; Gallina et al,
2021), whereas outside the context of DNA replication this is medi-
ated indirectly by the coupling of SUMOylation and RNF4 STUbL
activity. Importantly, we provide direct evidence that DPC
SUMOylation neither interferes with nor stimulates replication-
coupled DPC resolution, indicating that these modes of DPC
processing represent fully independent repair pathways. Indeed,
both DPC ubiquitylation and degradation by SPRTN and/or the
proteasome were unaffected when the DPC was SUMOylated prior
to DNA replication or if DNA replication occurred in the absence of
de novo SUMOylation. Thus, SUMOylated DPCs, which are likely
generated throughout the cell cycle and could be encountered by
the replication machinery, are unlikely to compete with rapid
SPRTN- and ubiquitin/proteasome-driven DPC proteolysis at the
replication fork or ssDNA gaps (Fig 6). Instead, our new findings
suggest and provide a mechanistic rationale for a critical role of
SUMO-driven DPC resolution in complementing replication-coupled
DPC repair by either clearing the lesions prior to DNA replication
or removing DPCs generated after the passage of replication forks,
the latter process being essential for subsequent faithful chromoso-
mal segregation and cell division (Fig 6). In agreement with our
data, a recent study showed that topoisomerase-type crosslinks,
which are flanked by DNA breaks, can also be targeted for protea-
somal degradation by RNF4 (Sun et al, 2020). Likewise, previous
studies described an essential role of STUbLs in counteracting
topoisomerase DPCs in yeast (Heideker et al, 2011; Steinacher et al,
2013; Wei et al, 2017; Sun et al, 2020). SUMO-driven ubiquitylation
and removal of DPCs thus emerges as a conserved pathway for
eukaryotic cells to resolve these toxic lesions, and it seems likely
that this mechanism can target a wide range of DPCs encountered
in the genome. Of note, repair of TOP2 DPCs can also occur in the
absence of DPC proteolysis via the ZATT-TDP2 axis, which may
represent the default option for resolving these lesions (Schellen-
berg et al, 2017). Thus, RNF4-mediated DPC destruction might
provide an alternative or back-up pathway when target-specific
DPC repair processes are not available due to the nature of the
crosslink or cell cycle stage.
The SUMO-RNF4 DPC resolution pathway is essential for faithful
cell division
Surprisingly, although DNMT1 DPCs generated behind the replica-
tion fork are efficiently sensed by cells as evidenced by their robust
crosslinking-dependent SUMOylation and subsequent ubiquitylation,
we found that these DPCs do not trigger detectable levels of conven-
tional DNA damage signalling, suggesting that cells do not mount an
effective interphase checkpoint response to DPCs in otherwise
undamaged dsDNA and consequently fail to prevent cells harbouring
unresolved DPCs from entering mitosis. This in turn has a severe
impact on chromosome stability, as demonstrated by our finding that
a large proportion of cells in which DNMT1 DPC repair is suppressed
by RNF4 knockdown display defective chromosome segregation
leading to aneuploidy. Preventing SUMOylation-dependent removal
of formaldehyde-induced DPCs likewise undermines faithful mitotic
chromosome segregation, suggesting this is a general feature of unre-
solved DPCs that are not accompanied by DNA breakage. While it
seems likely that this inability to trigger activation of the DNA
damage checkpoint may apply selectively to DPCs in uninterrupted
duplex DNA such as those generated by 5-azadC or reactive aldehy-
des, the potential of these lesions for undermining accurate chromo-
some segregation clearly underscores the importance of efficient
SUMO-driven post-replicative DPC resolution mechanisms for main-
taining chromosomal integrity, considering also that the formalde-
hyde dose used in our experiments is close to its estimated
intracellular concentration in human cells (approx. 400 µM; Euro-
pean Food Safety Authority, 2014). One potential mechanism for
facilitating efficient post-replicative resolution of SUMOylated DPCs
could entail cyclin-CDK-driven stimulation of their RNF4-mediated
ubiquitylation, in keeping with previous work showing that RNF4 E3
ubiquitin ligase activity is regulated by stimulatory phosphorylation
by CDKs (Luo et al, 2015). Indeed, we found that mitosis-like egg
extract potentiated RNF4-mediated DPC ubiquitylation in a CDK-
dependent manner. Thus, the cell cycle-dependent increase in
cyclin-CDK activity may progressively stimulate RNF4-mediated
ubiquitylation of SUMO-modified DPCs, ensuring their rapid removal
during late stages of the cell cycle. We note in this context that levels
of reactive oxygen species (ROS), which fuel the generation of alde-
hydes that are strong drivers of DPC formation, have been shown to
fluctuate during the cell cycle and peak in G2 phase (Singh et al,
2013; Patterson et al, 2019). Based on our findings, we propose that
the SUMO-RNF4 axis provides a crucial salvage pathway for efficient
clearance of DPCs formed after DNA replication but prior to mitotic
entry, thus protecting against the deleterious impact of DPCs on
faithful chromosome segregation (Fig 6). Precisely how unresolved
DPCs undermine the integrity of mitosis remains to be established,
but it is possible that a high load of DPCs could compromise the
initial steps of chromosome condensation.
Is SUMOylation a global modulator of protein residence time
on DNA?
A body of previous work has shown that in addition to DPCs, many
non-covalently bound proteins are specifically modified by
SUMOylation when associated with chromatin to promote their
displacement from this compartment, at least in some cases medi-
ated by STUbL activity (Galanty et al, 2012; Luo et al, 2012; Gibbs-
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Seymour et al, 2015; Guerillon et al, 2020). Based on these observa-
tions, it is tempting to speculate that SUMOylation may provide a
general mechanism for limiting the interaction of proteins with DNA
or chromatin, with the magnitude of SUMOylation correlating with
the residence time of the bound protein and/or its affinity for DNA
or chromatin. In such a scenario, DPCs represent an extreme case
given their covalent trapping on DNA, providing an attractive ratio-
nale for the remarkably potent SUMOylation response targeting 5-
azadC- and formaldehyde-induced DPCs in cells (Borgermann et al,
2019). In further agreement with this model, we found that the non-
covalent trapping of PARP1 on DNA by PARP inhibitors also triggers
its SUMO-dependent modification. Likewise, it is well established
that many transcription factors and chromatin remodellers are
targeted by SUMOylation. For instance, several studies have shown
that the SUMOylation of some transcription factors reduces their
affinity for or occupancy time on DNA (Rosonina et al, 2012; Tempe
et al, 2014; Akhter & Rosonina, 2016). Thus, SUMOylation appears
to be a mark placed on a multitude of diverse DNA-interacting
proteins to curb their association with DNA. In some instances,
SUMOylation of weak DNA interactors might be sufficient to lower
their affinity for chromatin, whereas for tightly bound proteins or
DPCs, SUMOylation may require subsequent ubiquitylation and
degradation by the proteasome. The recognized substrate promiscu-
ity of protein SUMOylation and its link to the ubiquitin-proteasome
system via STUbLs could render this modification well suited as a
non-specific modifier of multitudinous DPCs and other non-
covalently bound proteins whose chromatin occupancy must be
constrained to maintain the integrity and functionality of the
genome. Although we found that PIAS4 is clearly the main mediator
of M.HpaII DPC SUMOylation in Xenopus egg extracts, catalyses
DPC SUMOylation in vitro and is recruited to DNMT1 DPC sites in
cells, it appears to act redundantly with one or more other SUMO
E3s in driving the dramatic cellular DNMT1 SUMOylation response
accompanying its crosslinking to DNA. Consistent with an ability of
PIAS4 to SUMOylate different DPCs, it was recently shown to
SUMOylate TOP1 and TOP2 DPCs in cells, although also in this
setting its absence only had a partial impact on TOP1/TOP2 DPC
SUMOylation (Sun et al, 2020).
Together with the recent discoveries of several DPC removal
enzymes, our work highlights the versatile toolbox available to cells
to resolve these toxic lesions at different stages of the cell cycle. In
some cases, these DPC-processing enzymes are uniquely tailored for
specific types of crosslinks, as in the case of TOP1/2 adduct removal
by TDP1/2. When specialized DPC resolution pathways cannot be
utilized, cells instead rely on more generic complementary DNA
replication-coupled and SUMO-driven replication-independent
repair pathways to non-discriminately remove the large diversity of
DPCs and thereby mitigate the threat they pose to genome integrity.
Materials and Methods
Cell culture
Human HeLa, U2OS and RPE-1 cells were obtained from ATCC.
HeLa and U2OS cells were propagated in Dulbecco’s modified
Eagle’s medium (DMEM) and RPE-1 cells were grown in mix of
DMEM and F-12 medium supplemented with 10% (v/v) foetal
bovine serum and 1% penicillin–streptomycin. Cells were cultured
in humidified incubators at 37°C with 5% CO2 and were regularly
tested negative for mycoplasma infection. The cell lines were not
authenticated. HAP1 cells were cultured in IMDM-medium (Gibco)
supplemented with 10% heat-inactivated foetal calf serum (FCS;
Thermo Fisher Scientific) and penicillin–streptomycin–glutamine
solution (Gibco). All HAP1 cell lines were monitored for ploidy and
authenticated by genotyping. HAP1 cells were co-transfected with a
blasticidin resistance vector and the CRISPR/Cas9 plasmid pX330
containing a RNF4 targeting sgRNA (50-CTGCATGGACGGATAC
TCAG-30). Cells were selected in 20 µg/ml blasticidin for 2 days and
clonally expanded to generate isogenic cell lines. RNF4 KO cell lines
were validated by DNA sequencing. HeLa cells stably expressing
GFP-DNMT1 (HeLa/GFP-DNMT1) were described previously (Borg-
ermann et al, 2019). Plasmids encoding Myc-PIAS4 WT or a catalyt-
ically inactive C342A mutant (CI) were generated by inserting the
corresponding cDNAs into pcDNA3 (Invitrogen) containing an N-
terminal Myc-tag. Plasmid DNA transfections were performed using
FuGENE 6 (Promega), Novagen GeneJuice (Merck) or Lipofectamine
2000 (Invitrogen), according to the manufacturers’ protocols. Cell
cycle synchronizations were performed as described (Ma & Poon,
2011). Briefly, HeLa, U2OS or RPE-1 cells were synchronized at the
G1/S transition by incubating cells with 2 mM thymidine for 13–
15 h, followed by 9-h release with fresh medium and subsequent
thymidine incubation for an additional 13–15 h. HAP1 cells were
synchronized by single treatment with thymidine for 16 h. Mitotic
cells were obtained by treatment with nocodazole followed by
mechanical shake-off.
Unless otherwise indicated, the following doses of drugs and
genotoxic agents were used: 5-aza-20-deoxycytidine (5-azadC;
10 lM, Sigma-Aldrich), formaldehyde (500 µM, Thermo Scientific
Pierce), aphidicolin (APH; 10 µM, Sigma-Aldrich), hydroxyurea
(HU; 2 mM, Sigma-Aldrich), MG132 (20 lM, Sigma-Aldrich) ML-
792 (SUMOi; 2 lM, synthesized by MedKoo Biosciences), MLN-
7243 (UBi; 5 lM, Active Biochem), nocodazole (0.04 lg/ml, Sigma-
Aldrich), reversine (MPS1i; 0.5 µM, Cayman Chemicals), thymidine
(2 mM, Sigma-Aldrich) and ionizing radiation (IR; 10 Gy).
siRNAs
siRNA transfections were performed using Lipofectamine RNAiMAX
(Invitrogen) according to the manufacturer’s instructions. All
siRNAs were used at a final concentration of 20 nM unless other-
wise indicated. The following siRNA oligonucleotides, whose knock-
down efficiencies were validated where indicated, were used:
non-targeting control (CTRL): 50-GGGAUACCUAGACGUUCUA-30;
MMS21: 50-CUCUGGUAUGGACACAGCUTT-30 (Potts & Yu, 2005);
RanBP2: 50-GGACAGUGGGAUUGUAGUGTT-30 (Joseph et al, 2004);
PIAS1: 50-UAUUAAUGUAGCUUGUGUCUACAGC-30 (Guerillon et al,
2020); PIAS2: 50-CUUGAAUAUUACAUCUUUATT-30 (Galanty et al,
2009); PIAS3: 50-CCCUGAUGUCACCAUGAAATT-30 (Galanty
et al, 2009); ZATT: 50-CAGAAUUCAGGACACAAAUU-30 (Borger-
mann et al, 2019); DNMT1: 50-CGGUGCUCAUGCUUACAAC-30;
PIAS4 #1: 50-GGAAUAAGAGUGGACUGAATT-30 and PIAS4 #3:
50- AGCUGCCGUUCUUUAAUAUTT-30 (Fig EV2L); PIAS4 (30UTR):
50-UAGCCACAGAUGUGUUGUAUU-30 (Fig EV2N); RNF4 #1: 50-GAA
UGGACGUCUCAUCGUUTT-30 and RNF4 #2: 50-GAAUGGACGUCU
CAUCGUU-30 (Fig EV1C); RNF111 #1: 50-AGAAGGAAAUGAAUG
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GUAATT-30 and RNF111 #2: HSS182646 (Thermo Scientific)
(Fig EV1D; a mix of siRNA #1 and #2 was used in all experiments).
Immunochemical methods, chromatin fractionation
and antibodies
Immunoblotting was performed as previously described (Poulsen
et al, 2012). To prepare cell extracts, cells were lysed in EBC buffer
supplemented with protease and phosphatase inhibitors on ice for
20 min, and lysates were cleared by centrifugation (16,300 × g,
20 min). For immunoprecipitation, cells were lysed in denaturing
buffer (20 mM Tris, pH 7.5; 50 mM NaCl; 1 mM EDTA; 0.5% NP-40;
0.5% SDS, 0.5% sodium deoxycholate; 1 mM DTT) supplemented
with protease and phosphatase inhibitors, followed by sonication.
Lysates were then cleared by centrifugation (16,300 × g, 20 min).
Cleared lysates were incubated with GFP-trap agarose (Chromotek)
overnight with constant agitation at 4°C. After extensive washing of
the beads, GFP-tagged proteins were eluted by boiling in 2× Laemmli
sample buffer for 5 min. For chromatin fractionation, cells were first
lysed in buffer 1a (10 mM Tris, pH 8.0; 10 mM KCl; 1.5 mM MgCl2;
0.34 M sucrose; 10% glycerol; 0.1% Triton X-100) supplemented
with protease and phosphatase inhibitors on ice for 5 min, followed
by centrifugation (2,000 × g, 5 min) to recover the soluble proteins.
Pellets were then washed extensively twice in buffer 1b (buffer 1a
supplemented with 500 mM NaCl), followed by resuspension in
buffer 2 (50 mM Tris, pH 7.5; 150 mM NaCl; 1% NP-40; 0.1% SDS;
1 mMMgCl2; 125 U/ml benzonase) supplemented with protease and
phosphatase inhibitors. Lysates were incubated in thermomixer
(37°C, 1,000 rpm, 15 min), and solubilized chromatin-bound
proteins were obtained by centrifugation (16,300 × g, 10 min).
Antibodies to human proteins used in this study included: actin
(clone C4, MAB1501, Merck (1:20,000 dilution), RRID:AB_
2223041); ATM (ab78, Abcam (1:1,000), RRID:AB_306089); ATM-
pS1981 (4526, Cell Signaling Technology (1:1,000), RRID:AB_
2062663); CDC27 (sc-9972, Santa Cruz, RRID:AB_627228); CDK1-
pY15 (ab47594, Abcam (1:1,000), RRID:AB_869073); CHK1 (sc-
8408, Santa Cruz (1:500), RRID:AB_627257); CHK1-pS317 (2344S,
(Cell Signaling Technology (1:1,000), RRID:AB_331488); cyclin A
(sc-751, Santa Cruz (1:1,000), RRID:AB_631329); cyclin B (610220,
BD Bioscience (1:1,000), RRID:AB_397617); GFP (11814460001
(clones 7.1 and 13.1), Roche (1:1,000), RRID:AB_390913; ab6556,
Abcam (1:5,000), RRID:AB_305564); histone H2AX (2595S, Cell
Signaling Technology (1:1,000), RRID:AB_10694556); histone c-
H2AX (05-636, Millipore (1:1,000), RRID:AB_309864); histone H3
(ab1791, Abcam (1:50,000), RRID:AB_302613); histone H3-pS10
(06-570, Millipore (1:1,000), RRID:AB_310177); KAP1 (A300-274A,
Bethyl Laboratories (1:1,000), RRID:AB_185559); KAP1-pS824
(A300-767A, Bethyl (1:1,000), RRID:AB_669740); NF-jB p65 (sc-372,
Santa Cruz (1:2,000); RRID:AB_632037); RNF4 (Maure et al, 2016)
(1:6000)); PIAS4 (sc-166706, Santa Cruz (1:1,000); RRID: AB_
2164374); SUMO2/3 (ab3742, Abcam (1:1,000), RRID:AB_304041;
ab81371 (8A2), Abcam (1:200), RRID:AB_1658424); ubiquitin (sc-
8017 (P4D1), Santa Cruz (1:1,000), RRID:AB_628423); ubiquitin
(K48) (05-1307, Millipore (1:1,000), RRID:AB_1587578). Polyclonal
sheep antibody to DNMT1 was raised against full-length recombinant
human DNMT1 purified from bacteria (Borgermann et al, 2019).
Antibodies to Xenopus proteins used in this study and previously
described include the following: M.HpaII (Larsen et al, 2019); ORC2
(Fang & Newport, 1993); PARP1 (Ryu et al, 2010); PIAS4 (Azuma
et al, 2005); PSMA1 (Larsen et al, 2019); PSMA3 (Larsen et al,
2019). RNF4 antibody was raised against the following peptides:
RNF4 CT-L Ac-CRKKLNHKQYHPIYI-OH and RNF4 CT-S Ac-
CRKKLNNKQYHPIYV-OH (New England Peptide). The following
commercially available antibodies were used: Histone H3 (9715S,
Cell Signaling Technology), PAR (83732, Cell Signaling Technology).
Immunofluorescence and high-content image analysis
Cells were pre-extracted on ice in stringent pre-extraction buffer
(10 mM Tris–HCl, pH 7.4; 2.5 mM MgCl2; 0.5% NP-40; 1 mM
PMSF) for 8 min and then in ice-cold PBS for 2 min prior to fixa-
tion with 4% formaldehyde for 15 min. If not pre-extracted, cells
were subjected to permeabilization with PBS containing 0.2%
Triton X-100 for 5 min prior to blocking. Coverslips were blocked
in 10% BSA and incubated with primary antibodies for 1 h at
room temperature, followed by staining with secondary antibodies
and DAPI (Alexa Fluor; Life Technologies) for 1 h at room temper-
ature. Coverslips were mounted in MOWIOL 4-88 (Sigma). Manual
image acquisition was performed with a Leica AF6000 wide-field
microscope (Leica Microsystems) equipped with HC Plan-
Apochromat 63×/1.4 oil immersion objective, using standard
settings and LAS X software (Leica Microsystems). Raw images
were exported as TIFF files, and if adjustments in image contrast
and brightness were applied, identical settings were used on all
images of a given experiment. For automated image acquisition,
images were acquired with Olympus IX-81 wide-field microscope
equipped with an MT20 Illumination system, Olympus UPLSAPO
20×/0.75 NA objective, and a digital monochrome Hamamatsu
C9100 CCD (charge-coupled device) camera was used. Automated
and unbiased image analysis was carried out with the ScanR anal-
ysis software. Data were exported and processed using Spotfire
(TIBCO Software Inc.).
Quantification of mRNA levels by RT–qPCR
RNA was purified from cells (RNeasy kit, Qiagen), and cDNA was
generated by PCR with reverse transcription (iScript cDNA Synthesis
Kit, Bio-Rad) according to the manufacturer’s instructions. Real-
time quantitative PCR was performed using the Stratagene Mx3005P
System and Brilliant III Ultra-Fast SYBR Green QPCR Master Mix
(Agilent). GAPDH mRNA levels were used as a control for normal-
ization. For amplification of the indicated cDNAs, the following
primers were used: GAPDH (forward): 50-CAGAACATCATCCC
TGCCTCTAC-30; GADPH (reverse): 50-TTGAAGTCAGAGGAGACC
ACCTG-30; RNF111 (forward): 50-TGCATCCTCACTTGGCCCAT-30;
RNF111 (reverse): 50-TCAGTTCCTCAAAATTGCCCCTG-30.
Clonogenic survival assays
Approx. 400 cells were plated per 60-mm plate and treated with 5-
azadC for 24 h or formaldehyde for 30 min. Cells were then washed
with PBS twice, and fresh medium was replenished. Colonies were
fixed and stained after approximately 2 weeks with cell staining
solution (0.5% w/v crystal violet, 25% v/v methanol). The number
of colonies were quantified using a GelCountTM (Oxford Optronix)
colony counter.
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Flow cytometry
Cells were fixed in ice-cold 80% ethanol, and DNA was stained with
propidium iodide (0.1 mg/ml) containing RNase (20 lg/ml) for
30 min at 37°C. Flow cytometry analysis was performed on a FACS
Calibur (BD Biosciences) using CellQuest Pro software (version 6.0;
Becton Dickinson). The data were analysed using FlowJo software
(version 10.6).
Live cell imaging
Cells were seeded onto an Ibidi dish (Ibidi) the day before acquisi-
tion. Medium were changed to Leibovitz’s L15 medium (Life Tech-
nologies) supplemented with 10% FBS and SiR-DNA (100 nM,
Spirochrome) prior to filming. Live cell imaging was performed on a
Deltavision Elite system using a 40× oil objective (GE Healthcare).
Images (DIC and Cy5 channels) were acquired every 5 min for 18 h.
Three z-stacks of 5 lm were imaged. SoftWork software (GEHealth-
care) was used for data analysis.
In vitro STUbL assays
HeLa/GFP-DNMT1 cells treated or not with 5-azadC were lysed in
denaturing buffer supplemented with protease and phosphatase
inhibitors, and lysates were sonicated and cleared by centrifugation.
GFP-tagged DNMT1 was then purified on GFP-Trap agarose (Chro-
motek) followed by extensive washing in denaturing buffer. The
beads were equilibrated in ubiquitylation assay buffer (50 mM Tris
pH 7.5; 150 mM NaCl; 5 mM MgCl2; 2 mM NaF; 2 mM ATP; 6 mM
DTT; 0.1% NP-40) and incubated with recombinant proteins
(100 nM E1, 500 nM E2 (UbcH5a), 20 µM HA-ubiquitin, and
0.55 µM RNF4 with shaking at 37°C for 1 h. Bound material was
washed in denaturing buffer, eluted by boiling in 2× Laemmli
sample buffer for 5 min and analysed by immunoblotting.
Xenopus egg extracts
Egg extracts were prepared using Xenopus laevis (Nasco Cat
#LM0053MX, LM00715MX). All experiments involving animals
were approved by the Danish Animal Experiments Inspectorate and
conform to relevant regulatory standards and European guidelines.
Preparation of Xenopus egg extracts was performed as described
previously (Lebofsky et al, 2009; Sparks & Walter, 2019). For high-
speed supernatant (HSS) preparation, 6 female frogs (Nasco) were
primed by injection with 80 IU of human chorionic gonadotropin
(hCG, Sigma). 2–7 days after priming, frogs were injected with
625 IU of hCG and placed in individual tanks containing 100 mM
NaCl. 18-20 h post injection, eggs were collected and used for
extract preparation. Eggs were first dejellied in cysteine buffer for
7 min (2.2% cysteine-HCl, pH 7.7), washed three times in 0.5×
MMR buffer (final concentration: 50 mM NaCl, 1 mM KCl,
0.25 mM MgSO4, 1.25 mM CaCl2, 2.5 mM HEPES, 0.05 mM EDTA,
pH 7.8) and washed three times in ELB sucrose buffer (2.5 mM
MgCl2, 50 mM KCl, 10 mM HEPES, 250 mM sucrose, 1 mM DTT,
50 µg/ml cycloheximide, pH 7.8). Eggs were packed for 1 min at
176 × g and crushed for 20 min at 20,000 × g in a swing bucket
rotor at 4°C in the presence of cytochalasin B (2.5 µg/ml), aprotinin
(5 µg/ml) and leupeptin (5 µg/ml). Crude interphase extract was
recovered post-centrifugation and spun in ultracentrifuge for
90 min at 260,000 × g at 2°C following addition of cycloheximide
(50 µg/ml), DTT (1 mM), aprotinin (10 µg/ml), leupeptin (10 µg/
ml) and cytochalasin B (5 µg/ml). Following centrifugation, the
lipid layer on top was removed. The soluble HSS was harvested,
snap frozen in 33 µl aliquots and stored at 80°C. For nucleoplas-
mic egg extract (NPE), 20 female frogs were injected and the crude
interphase extract was prepared in the same manner as for HSS.
Once collected, the crude interphase extract was supplemented with
cycloheximide (50 µg/ml), DTT (1 mM), aprotinin (10 µg/ml),
leupeptin (10 µg/ml), cytochalasin B (5 µg/ml) and nocodazole
(3.3 µg/ml). The extract was spun at 20,000 × g at 4°C for 10 min.
The lipid layer on top was removed and the interphase extract
decanted to a new tube. The interphase extract was supplemented
with ATP (final concentration: 2 mM), phosphocreatine (20 mM)
and creatine phosphokinase (5 µg/ml), and nuclear assembly reac-
tions were initiated by adding demembranated sperm chromatin to
a final concentration of 4,400/µl. The nuclear assembly reaction
was incubated at room temperature for 60–85 min and then spun
for 2 min at 20,000 × g in a swing bucket rotor. The nuclear layer
on top was recovered and then spun in a swinging bucket rotor at
260,000 × g at 2°C for 30 min. Lipids on top were removed and the
clear soluble NPE was harvested. NPE (10 µl) aliquots were snap-
frozen and kept at 80°C.
CSF-arrested whole egg extracts were prepared as previously
described (Hannak & Heald, 2006) but with the following modifi-
cation: The low speed supernatant extract recovered from the
Hannak et al protocol was transferred to a new tube and spun at
260,000 × g at 2°C for 2 h. The soluble fraction was collected and
snap frozen in single use 20 µl aliquots.
For replication-independent reactions, plasmid DNA was incu-
bated at 6 ng/µl in the indicated extract. NPE was supplemented
with 4 mM DTT, 20 mM phosphocreatine, 2 mM ATP, 5 µg/ml
creatine phosphokinase; HSS and CSF-arrested extract were supple-
mented with nocodazole (3 µg/ml), 20 mM phosphocreatine, 2 mM
ATP, 5 µg/ml creatine phosphokinase. Plasmid DNA was recovered
via DPC pull-down as described below.
As previously described (Duxin et al, 2014) for DNA replication,
plasmids were first incubated in HSS (7.5 ng DNA/µl HSS) for 20-
30 min at room temperature to license the DNA. Two volumes of
NPE were then added to 1 volume of licensing reaction to initiate
replication. To block de novo SUMOylation, ML-792 SUMO-E1 inhi-
bitor was added to extracts to a final concentration of 50 µM. To
block de novo ubiquitylation MLN-7243 was added to a final
concentration of 133 µM. For DNA labelling, reactions were supple-
mented with [a-32P]dATP. To analyse plasmid replication interme-
diates, 1 µl of each reaction was added to 5 µl of replication stop
solution A (5% SDS, 80 mM Tris pH 8.0, 0.13% phosphoric acid,
10% Ficoll) supplemented with 1 µl of Proteinase K (20 mg/ml)
(Roche). Samples were incubated for 1 h at 37°C prior to separation
by 0.9% native agarose gel electrophoresis and visualization using a
phosphorimager (Lebofsky et al, 2009).
Immunodepletion and add-back experiments
To immunodeplete PIAS4, RNF4 or PSMA1 from Xenopus egg
extracts, one volume of Protein A Sepharose Fast Flow (PAS) (GE
Health Care) was mixed with either five volumes of PIAS4 serum
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antibody, five volumes of affinity purified RNF4 peptide antibody
(1 mg/ml) or 10 volumes of affinity purified PSMA1 peptide anti-
body (1 mg/ml) and incubated overnight at 4°C. The beads were
subsequently washed twice with 500 µl PBS, once with ELB-
sucrose (10 mM HEPES pH 7.7, 50 mM KCl, 2.5 mM MgCl2, and
250 mM sucrose), twice with ELB supplemented with 0.5 M NaCl
and twice with ELB-sucrose. Five volumes of NPE or CSF arrested
extract was then depleted by mixing with one volume of antibody-
bound beads and incubated at room temperature for 15 min. This
was repeated once for PIAS4, twice for RNF4 and three times
for PSMA1.
For rescue experiments, PIAS4 WT or SIM1/2* were added to
depleted extracts to a final concentration of 10 ng/µl in the reaction.
RNF4 WT or a catalytically inactive C130A mutant were added to a
final concentration of 7 ng/µl or five times this amount where indi-
cated (5xRNF4).
Preparation of DNA constructs
To generate p4xDPC and p4xDPCSUMO, pJLS3 (Sparks et al, 2019)
was nicked with Nt.BbvCI (New England Biolabs) and ligated with
the following oligo containing a fluorinated cytosine: 50-TCAGCATC
[C5-Fluoro-dC]GGTAGCTACTCAATC[C5-Fluoro-dC]GGTACC-30 and
subsequently crosslinked to M.HpaII-His6 or SUMOΔGG-M.HpaII-
His6, respectively, as previously described (Duxin et al, 2014).
Briefly, the fluorinated plasmid DNA was gel purified and mixed
with M.HpaII-His6 or SUMOΔGG-M.HpaII-His6 in reaction buffer
(50 mM Tris–HCl pH 7.5, 5 mM 2-mercaptoethanol, 10 mM EDTA)
supplemented with 100 µM of S-adenosylmethionine (NEB) for
12 hr at 37°C.
pDPCssDNA and pDPC were previously described in (Larsen et al,
2019). p2xDPCLeads was previously described in (Larsen et al, 2019)
as pDPC2xLeads. p2xDPCSUMOLeads and pDPCSUMOssDNA were gener-
ated similarly to p2xDPCLeads and pDPCssDNA, but plasmid DNA was
crosslinked to SUMOΔGG-M.HpaII-His6 instead of M.HpaII-His6.
Protein expression and purification
M.HpaII-His6 was expressed and purified as previously described
(Duxin et al, 2014). Briefly, pHpaII-Avitag-His6 was transformed in
T7 Express Competent E. coli cells (NEB), which were cultured in
the presence of 100 µg/ml ampicillin until the OD600 reached 0.7.
The culture was supplemented with 0.5 mM IPTG for 3 h, collected
by centrifugation and resuspended in 15 ml Lysis Buffer (20 mM
Tris pH 8.5, 500 mM KCl, 10% glycerol, 10 mM imidazole and
protease inhibitors (Roche)). Cells were lysed by sonication and
cleared by centrifugation at 20,000 × g for 30 min. Cleared lysate
was applied onto Ni-NTA resin (Qiagen). The resin was washed
with 25 ml of Lysis Buffer containing 30 mM imidazole and the
protein eluted with Elution Buffer (20 mM Tris pH 8.5, 100 mM
KCl, 10% glycerol and 250 mM imidazole). Eluate was dialysed
overnight in Storage Buffer (20 mM Tris pH 8.5, 100 mM KCl,
1 mM DTT, 30% glycerol) and protein aliquots snap frozen and
kept at 80°C. SUMOΔGG-M.HpaII was expressed and purified in
the same way.
LacI-biotin protein was purified from T7 Express Competent
cells (NEB) (Duxin et al, 2014). Briefly, pET11a-LacI and pBirAcm
(Avidity) were co-transformed and cells cultured in the presence of
100 µg/ml ampicillin and 34 µg/ml chloramphenicol at 37°C until
OD600 reached 0.6. The culture was supplemented with 1 mM IPTG
and 50 µM biotin for 2 h. Cells were collected by centrifugation
and resuspended in Buffer 1 (50 mM Tris pH 7.5, 5 mM EDTA,
100 mM NaCl, 10% sucrose, 1 mM DTT, protease inhibitors
(Roche), 0.2 mg/ml lysozyme (Sigma), 0.1% Brij 58) and rotated
for 30 min at room temperature. The cell lysate was pelleted by
centrifugation for 60 min at 20,000 × g, and the insoluble pellet
was resuspended in 10 ml of Extraction Buffer (50 mM Tris pH 7.5,
5 mM EDTA, 1 M NaCl, 30 mM IPTG, 1 mM DTT and protease
inhibitors). The resuspended pellet was homogenized by sonication
and pelleted again for 60 min at 20,000 × g. The supernatant was
collected, and 1% polymin P was added to 0.045%. Lysate was
rotated for 30 min at 4°C and pelleted at 20,000 × g for 20 min.
The supernatant was transferred to a new tube, and ammonium
sulphate was added to a final saturation of 37% followed by rota-
tion for 30 min at 4°C. The pellet was recovered and resuspended
in 2 ml of Wash Buffer (50 mM Tris pH 7.5, 1 mM EDTA, 100 mM
NaCl, 1 mM DTT and protease inhibitors). The resuspension was
applied to a column containing 1 ml of softlink avidin resin and
incubated for 1 h at 4°C. The column was washed with 15 ml of
Wash Buffer, and the protein eluted with Elution buffer (50 mM
Tris pH 7.5, 1 mM EDTA, 100 mM NaCl, 1 mM DTT and 5 mM
biotin). Protein was dialyzed overnight with Dialysis Buffer
(50 mM Tris pH 7.5, 1 mM EDTA, 150 mM NaCl, 1 mM DTT and
30% glycerol) and stored at 80°C.
Xenopus RNF4.L cDNA (Horizon) was cloned into pET28b using
primers 50-ATGCCATATGACAGCAGTGACTG-30 and 50-ACTGAAG
CTTTCATATATATATAGGGTGATATTG-30 and mutations were
introduced via QuikChange Site-directed mutagenesis. RNF4 WT or
C130A were transformed into T7 Express Competent E.coli cells
(NEB) and grown in the presence of 50 µg/ml of kanamycin.
Expression was induced with 100 µM IPTG for 4 h at 37°C. One liter
of culture was harvested and lysed in 25 ml lysis buffer, pH 7.4
(50 mM Tris–HCl, 300 mM NaCl, 2 mM MgCl2, 1 mM DTT, 1 tablet
complete/50 ml) via sonication. The lysate was supplemented with
25 U/ml of benzonase and incubated for 20 min at room tempera-
ture and centrifuged subsequently at 22,000 × g for 1 h at 4°C. The
supernatant was bound to 2 ml bead slurry of Ni-NTA resin (Qia-
gen) for 2 h rotating at 4°C. The beads were washed with 60 ml
wash buffer (50 mM Tris–HCl, 300 mM NaCl, 2 mM MgCl2, 1 mM
DTT, 0.1% Triton X-100) in total. The protein was eluted from the
resin with elution buffer (50 mM Tris–HCl, 300 mM NaCl, 2 mM
MgCl2, 1 mM DTT, 10% glycerol, 300 mM imidazole) and dialyzed
with 50 mM Tris–HCl, 300 mM NaCl, 2 mM MgCl2, 1 mM DTT,
10% glycerol overnight and with fresh dialysis buffer for two addi-
tional h the following day and stored at 80°C.
Expression and purification of human RNF4 proteins (WT,
*RING and *SIM mutants) were done as previously described
(Tatham et al, 2008; Plechanovova et al, 2011).
Xenopus PIAS4 (PIASc) WT and SIM1/2* were purified as
previously described (Azuma et al, 2005). Briefly, the protein
was expressed in E. coli and purified through a Talone-sepharose
FF column followed by a cation exchange column (SP-
sepharose). The peak elution was further separated by anion
exchange (Q-sepharose). The final protein preparation was
dialyzed into 150 mM NaCl, 25 mM HEPES, 5% glycerol and
1 mM DTT (pH 7.8).
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DPC pull-downs
DPC pull-downs were performed as previously described (Larsen
et al, 2019). Briefly, streptavidin-coupled magnetic beads (Dyn-
abeads M-280, Invitrogen; 5 µl per pull-down) were washed twice
with 50 mM Tris pH 7.5, 150 mM NaCl, 1mM EDTA pH 8.0,
0.02% Tween-20. Biotinylated LacI was added to the beads
(1 pmol per 5 µl of beads) and incubated at room temperature for
40 min. The beads were then washed four times with DPC pull-
down buffer (20 mM Tris pH 7.5, 150 mM NaCl, 2 mM EDTA pH
8, 0.5% IPEGAL-CA630) and then stored in the same buffer on ice
until needed. At the indicated times, 5 µl of reaction was with-
drawn and stopped in 300 µl of DPC pull-down buffer on ice.
After all time points were taken, 5 µl of LacI-coated streptavidin
Dynabeads was added to each sample and allowed to bind for 30–
60 min at 4°C with rotation. The beads were subsequently washed
four times with DPC pull-down buffer and then twice with Benzo-
nase buffer (20 mM Tris pH 7.5, 150 mM NaCl, 2 mM MgCl2,
0.02% Tween-20) before being resuspended in 15 µl Benzonase
buffer containing 1 µl Benzonase (Merck Millipore). Samples were
incubated for 1 h at 37°C to allow for DNA digestion and DPC
elution, after which the beads were pelleted and the eluate was
mixed with 2× Laemmli sample buffer for subsequent western
blotting analysis. For treatment with Ulp1 and Usp2, 5 µl of reac-
tion was withdrawn at the indicated time points and stopped in
300 µl of DPC pull-down buffer on ice. After all of the time points
were taken, 5 µl of LacI-coated streptavidin Dynabeads was added
to each sample and allowed to bind for 30–60 min at 4°C rotating.
The beads were subsequently washed four times with DPC pull-
down buffer and then once with Benzonase buffer (20 mM Tris
pH 7.5, 150 mM NaCl, 2 mM MgCl2, 0.02% Tween-20) and once
with DUB reaction buffer (500 mM Tris 7.5, 500 mM NaCl,
50 mM DTT) supplemented with 0.02% Tween-20 before being
resuspended in 15 µl DUB reaction buffer containing 1 µl Ulp1
and/or 1 µl Usp2. Samples were incubated for 45 min at 37°C and
subsequently washed once with Benzonase buffer (20 mM Tris pH
7.5, 150 mM NaCl, 2 mM MgCl2, 0.02% Tween-20) before being
resuspended in 15 µl Benzonase buffer containing 1 µl Benzonase
and incubated for 1 h at 37°C, after which the beads were pelleted
and the eluate was mixed with 2× Laemmli sample buffer for
subsequent immunoblotting analysis.
Chromatin spin-down
Demembranated Xenopus sperm chromatin was prepared as
described (Sparks & Walter, 2019) and stored at 80°C at a
concentration of 100,000 sperm chromatin/µl (320 ng/µl). Where
indicated, sperm chromatin was diluted to 50,000 sperm chro-
matin/µl in ELB buffer (10 mM HEPES pH 7.7, 50 mM KCl,
2.5 mM MgCl2, and 250 mM sucrose) and irradiated with 2000 J/
m2 of UV-C. Sperm chromatin was added at a final concentration
of 16 ng/µl to one volume of HSS and two volumes of NPE that
were premixed. At the indicated time points, 8 µl of reaction was
stopped in 60 µl of ELB buffer supplemented with 0.2% Triton X.
The mixture was carefully layered on top of a sucrose cushion
(10 mM HEPES pH 7.7, 50 mM KCl, 2.5 mM MgCl2 and 500 mM
sucrose) and spun for 1 min at 6,800 × g in a swing bucket centri-
fuge at 4°C. The chromatin pellet was carefully washed twice with
200 µl of ice-cold ELB buffer and resuspended in 2× Laemmli
buffer.
In vitro DPC SUMOylation
DPCs were SUMOylated by incubation overnight at 4°C with 100 ng
Sae1/Uba2, 300 ng Ubc9 and 3 µg SUMO2 per 10 µl reaction in 1x
Buffer S (50 mM HEPES pH 7.5, 100 mM NaCl, 10 mM MgCl2,
100 nM DTT, 2 mM ATP). Where indicated, PIAS4 was added to
the reaction at 80 ng/µl.
Extract exchange
Plasmid DNA was incubated in NPE for 60 min. SUMOylated DPCs
were then recovered via DPC pull-down, beads were washed with
ELB sucrose buffer (2.5 mM MgCl2, 50 mM KCl, 10 mM HEPES,
250 mM sucrose) supplemented with 0.02% Tween-20, dried and
whole egg CSF-arrested Xenopus egg extract was added to a final
DNA concentration of 6 ng/µl and incubated rotating at room
temperature. At the indicated time points, 5 µl was withdrawn and
stopped in DPC pull-down buffer (20 mM Tris pH 7.5, 150 mM NaCl,
2 mM EDTA pH 8, 0.5% IPEGAL-CA630). After the last time point,
the samples were incubated for 30 min rotating at 4°C and from here
on processed as described above for the DPC pull-down procedure.
Imaging of sperm chromatin
Sperm chromatin was incubated at 16 ng/µl in CSF-arrested extracts.
CDK inhibitor R547 was added where indicated at a final concentra-
tion of 10 µM. Samples were taken at 60 min, fixed in Hoechst stain
solution (8 µg/ml Hoechst, 7.4% formaldehyde, 200 mM sucrose,
10 mM HEPES pH 7.6). Images were obtained with a Leica AF6000
wide-field microscope (Leica Microsystems) equipped with HC Plan-
Apochromat 63×/1.4 oil immersion objective, using standard settings
and LAS X software (Leica Microsystems).
CHROMASS
CHROMASS experiments were performed as previously described
(R€aschle et al, 2015). Briefly, isolated sperm chromatin was treated
with 2,000 J/m2 of UV-C. Each reaction was performed in quadru-
plicate. The sperm chromatin was then incubated at a final concen-
tration of 16 ng/µl in non-licensing extracts in the presence or
absence of Talazoparib (10 µM) and SUMOi (50 µM). Reactions
were stopped after 30 min. Specifically, 10 µl of reaction was
stopped with 60 µl of ELB buffer supplemented with 0.2% Triton X,
and chromatin spin down performed as described above. The chro-
matin pellet was then resuspended in 50 µl denaturation buffer
(8 M urea, 100 mM Tris–HCl, pH 8.0) and transferred to a new low
binding tube. Cysteines were reduced (1 mM DTT for 15 min at RT)
and alkylated (0.55 M chloroacetamide for 40 min at RT protected
from light). Proteins were first digested with 0.5 µg Lys-C (2.5 h at
RT) and then with 0.5 µg trypsin at 30°C overnight. Peptides were
acidified with 10% trifluoroacetic acid (pH < 4), followed by addi-
tion of 400 mM NaCl and purified by stage tipping (C18 material).
For this, stage tips were first activated in 100% methanol, then equi-
librated in 80% acetonitrile/10% formic acid, and finally washed
twice in 0.1% formic acid. Samples were loaded on the equilibrated
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stage tips and washed twice with 50 µl 0.1% formic acid. StageTip
elution was performed with 80 ll of 25% acetonitrile in 0.1%
formic acid, eluted samples were dried to completion in a SpeedVac
at 60°C, dissolved in 10 ll 0.1% formic acid and stored at 20°C
until MS analysis.
MS acquisition
All CHROMASS samples were analysed on an EASY-nLC 1200
system (Thermo) coupled to a Q ExactiveTM HF-X Hybrid
Quadrupole-OrbitrapTM mass spectrometer (Thermo). Separation of
peptides was performed using 15-cm columns (75 µm internal diam-
eter) packed in-house with ReproSil-Pur 120 C18-AQ 1.9 µm beads
(Dr. Maisch). The columns were heated to 40°C using a column
oven (Sonation). Elution of peptides from the column was achieved
using a gradient ranging from buffer A (0.1% formic acid) to buffer
B (80% acetonitrile in 0.1% formic acid), at a constant flow rate of
250 nl/min. Gradient length was 100 min per sample, including
ramp-up and wash-out, with an analytical gradient of 76 min rang-
ing from 8 to 28% buffer B. Ionization of peptides was performed
using a NanoSpray FlexTM ion source (Thermo), with spray voltage
set to 2 kV, ion transfer tube temperature to 275°C and RF funnel
level to 40%. All samples were measured as two technical replicates
using 5 ll of the sample per injection, with differences outlined
below. MS RAW data files with a “b” appended to the file name
correspond to those analysed using alternative settings. Measure-
ments were performed with a full scan range of 300–1,750 m/z,
MS1 resolution of 60,000 (or alternatively 120,000), MS1 AGC target
of 3,000,000 and MS1 maximum injection time of 60 ms. Precursors
with charges 2–6 were selected for fragmentation using an isolation
width of 1.3 m/z and fragmented using higher-energy collision
disassociation (HCD) with a normalized collision energy of 25.
Precursors were excluded from re-sequencing by setting a dynamic
exclusion of 100 s. MS2 AGC target was set to 200,000, minimum
MS2 AGC target to 20,000, MS2 maximum injection time to 55 ms,
MS2 resolution to 30,000 and loop count to 14 (or alternatively 12).
MS data analysis
All MS RAW data were analysed using the freely available
MaxQuant software (Cox & Mann, 2008), version 1.5.3.30. Default
MaxQuant settings were used, with exceptions specified below. For
generation of theoretical spectral libraries, the Xenopus laevis
FASTA database was downloaded from UniProt on the 10th of
February, 2018. In silico digestion of proteins to generate theoretical
peptides was performed with trypsin, allowing up to 3 missed cleav-
ages. Maximum variable modifications per peptide were reduced to
3. Label-free quantification (LFQ) was enabled (Cox et al, 2014),
with “Fast LFQ” disabled, and “LFQ min. ratio count” set to 3.
Second peptide search was enabled. Matching between runs was
enabled, with an alignment window of 20 min and a match time
window of 1 min. Stringent MaxQuant 1% FDR was applied at the
PSM and protein levels (default).
MS data annotation and quantification
The Xenopus laevis FASTA database downloaded from UniProt
lacked comprehensive gene name annotation. Missing or
uninformative gene names were, when possible, semi-
automatically curated by drawing informative gene names from
UniProt, Xenbase, the Session et al database (Session et al, 2016)
or RefSeq (via Xenbase), otherwise InterPro annotations were
used. Quantification of the MaxQuant output files was performed
using the freely available Perseus software (Tyanova et al, 2016),
v1.5.5.3. For quantification, all protein LFQ intensity values were
log2 transformed, and proteins were filtered for valid (i.e. non-
zero) values in 4 out of 4 replicates (n = 4/4) in at least one
experimental condition. Missing values were imputed below the
global experimental detection limit at a downshift of 1.8 and a
randomized width of 0.3 (in log2 space; Perseus default). The
statistical significance of differences was evaluated using two-
tailed Student’s t-testing, with permutation-based FDR-control
applied at an s0 value (“fudge factor”) of 0.5. A first round of
quantification was performed where all UV-treated conditions were
individually compared to the control, and only proteins with a
positive ratio and an FDR-adjusted q-value of < 10% in at least
one of these comparisons were subjected to two-sample testing
within UV-treated conditions. Both P-values and FDR-adjusted q-
values are reported in Dataset EV1.
Data availability
The mass spectrometry proteomics data (Dataset EV1) have been
deposited to the ProteomeXchange Consortium via the PRIDE part-
ner repository with the dataset identifier PXD021947 (https://
www.ebi.ac.uk/pride/archive/projects/PXD021947). All other data
supporting the findings of this study are available within the article
and supplementary information.
Expanded View for this article is available online.
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